Absolute risk reduction in osteoporosis: Assessing treatment eYcacy by number needed to treat

Rheumatology International

Volumn 30, Issue 7, 2010, Pages 863-869

  Ringe, Johann D ^a   Doherty, John G ^b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SLIGO UNIVERSITY HOSPITAL   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Absolute risk reduction; Bisphosphonates; Osteoporosis; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

CLINICAL TRIAL; DRUG EFFICACY; HIP FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); RISK REDUCTION BEHAVIOR; THIOPHENES; TREATMENT OUTCOME;

EID: 77955094693     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1311-y     Document Type: Review

References (31)

1. US Department of Health and Human Services (DHHS) (2003) Report of the surgeon general's workshop on osteoporosis and bone health, pp 1-100. Available at http://www.surgeongeneral.gov/library/bonehealth/index.html. Accessed 11 Dec 2009.
2. Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4-S9.
3. Oden A, Dawson A, Dere W et al (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599-603.
4. van Schoor NM, Smit JM, Twisk JW et al (2003) Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 289:1957-1962.
5. Grant AM, Avenell A, Campbell MK et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621-1628.
6. Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669-683. (Pubitemid 43247138)
7. Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428.
8. Alonso-Coello P, Garcia-Franco AL, Guyatt G et al (2008) Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 336:126-129.
9. Barratt A, Wyer PC, Hatala R et al (2004) Tips for learners of evidence- based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 171:353-358.
10. Replogle WH, Johnson WD (2007) Interpretation of absolute measures of disease risk in comparative research. Fam Med 39:432-435.
11. Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293-300.
12. Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310:452-454.
13. McQuay HJ, Moore RA (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126:712-720.
14. Seeman E, Eisman JA (2004) 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust 180:298-303.
15. Committee for Medicinal Products for Human Use (CHMP) (2007) Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use. http://www.emea.europa.eu/pdfs/human/brmethods/1540407en.pdf. Accessed 9 Oct 2009.
16. Sox HC (2007) Straight talk about disease prevention. Ann Intern Med 146:891-892.
17. MacLaughlin EJ, Raehl CL (2008) ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. Am J Health Syst Pharm 65:343-357.
18. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of eVect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
19. Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249.
20. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
21. Cosman F, Borges JL, Curiel MD (2007) Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Clin Ther 29:1116-1127.
22. Adami S (2007) Bisphosphonate antifracture efficacy. Bone 41:S8-S15.
23. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
24. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637-645.
25. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
26. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468. (Pubitemid 38133766)
27. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
28. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822.
29. Agence Française de Sécurité Sanitaire des Produits (2006) Traitement de l'ostéoporose post-ménopausique. http://afssaps.sante.fr/pdf/5/rbp/ostemarg.pdf. Accessed 9 Oct 2009.
30. Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of longterm strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-1695.
31. Curtis JR, Westfall AO, Cheng H et al (2008) The benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101, 038 new bisphosphonate users. J Bone Miner Res 23:1435-1441.